Trial Profile
Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2019
Price :
$35
*
At a glance
- Drugs Naloxone (Primary)
- Indications Bulimia nervosa
- Focus Therapeutic Use
- Sponsors Opiant Pharmaceuticals
- 21 Feb 2019 Primary endpoint (Number of binging days from baseline to Week 8) has not been met, according to an Opiant Pharmaceuticals media release.
- 21 Feb 2019 Top-line results presented in the media release.
- 05 Nov 2018 According to an Opiant Pharmaceuticals media release, Last Patient, Last Visit (LPLV) occurred on November 2, 2018 in this trial.